Nipocalimab for adults with chronic inflammatory CIDP nerve disease
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests nipocalimab (an antibody medicine) to improve symptoms and control activity in chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disease that causes weakness and numbness. It may help reduce disease activity and disability, while checking safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can legally consent where you live
- You have a confirmed CIDP diagnosis (not a different nerve problem), including relapsing or steadily worsening forms
- Your disability score is in a certain range (INCAT) and can’t be too low or too high
- Your CIDP is currently “active” based on a disease-activity score (CDAS)
- You can be on certain treatments now or adjust them: low-dose steroids, or you can stop/slow treatment during the study
- You do NOT have “pure sensory” CIDP or CISP, and no other condition better explains your symptoms
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well current treatments work for people with CIDP (a nerve condition causing weakness). It tracks symptoms and daily function over time to help doctors understand which treatments may work best.
This trial tests a new drug called DNTH103 for adults with CIDP, a condition that affects nerves and causes weakness. It aims to see if the drug can help people who are currently on treatment, have tried treatment before, or are new to treatment.
This trial tests an investigational drug called Ripertamab for people with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve condition causing weakness and numbness. The goal is to see if the drug can improve symptoms compared to no additional treatment.
This study tests whether a drug called obinutuzumab can help people with chronic inflammatory demyelinating polyradiculoneuropathy (a condition where the immune system attacks the nerves, causing weakness and numbness). The drug aims to reduce the immune attack and improve symptoms.
This trial tests a new medicine, nipocalimab, for adults with moderate to severe lupus. It aims to see if the drug can help control lupus symptoms and reduce disease activity.
This trial tests whether a blood-filtering treatment called immunoadsorption can help people with CIDP. It is for adults who are already receiving or starting IVIg or MP therapy.
Hear when a new Polyradiculoneuropathy, Chronic Inflammatory Demyelinating trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.